Endocrine Flashcards
define Diabetic Ketoacidosis (DKA)
Glucose is not available for the body to use as energy, so instead, fat is used for fuel, producing
byproducts - ketones.
most common Precipitating factor of DKA
infection, missing insulin, or unknown
Dehydration, Acetone smell on breath, Abdominal tenderness, Tachycardia/hypotension/shock, AMS, Kussmaul respirations and Coffee ground emesis
DKA
dx of DKA
Glucose level >250mg/dL
● Bicarbonate
management of DKA
- fluids to dilute sugars
- give potassium
- know that sodium will be falsely low
role of insulin in DKA
Start 0.1 units/kg/hr IV drip. don’t worry about returning glucose to a normal level, instead focus on stoping DKA
Drugs can cause glucose intolerance
Glucocorticoids, anti-hypertensives
how do you dx DM?
two different accounts of fasting glucose >126, or random glucose >200 + symptoms or A1C >6.5
is DKA an acid or base disorder
acidosis
complications of DKA therapy
hypoglycemia, cerebral edema!!!!!
Sulfonylureas
Squeeze-stimulate pancreas to release more insulin
Biguanides
(bite) suppress hepatic gluconeogenesis
Thiazolidenediones (TZDs)
Increases sensitivity to insulin
Glipizide®, Glyburide®
sulfonylureas
Actos®, Avandia®
Thiazolidenediones
Metformin®
Biguanides
SE of sulfonylureas / Glipizide®, Glyburide®
hypoglycemia
SE of biguanides / Metformin
GI issues and Can cause lactic acidosis
SE of Thiazolidenediones ( actos and Avandia)
hepatitis & edema
Incretins:
Hormones released by small intestine enteroendocrine cells in response to dietary glucose, delays gastric emptying.
names of incretins (they end in TIDE)
GLP-1 analogs [GLP-1 receptor agonists]):
Albiglutide (advantage: once-weekly dosing)
Exenatide (synthetic version of exendin-4 found in Gila monster saliva!; extended release version is also once-weekly dosing)
Liraglutide (advantage: once-daily dosing)
Main disadvantage of incretins
must be administered by subcutaneous injection and cause GI SE
● Main risks:
pancreatitis, thyroid C-cell tumors
when are incretins used
incretin mimetics are recommended as potential 2nd
line treatment options to add to metformin (or other agents, including insulin) in
patients not achieving glycemic goals
we can block the enzyme that breaks down incretins using;
“DPP-4 inhibitors”
gliptins): o Sitagliptin o Saxagliptin o Linagliptin what are these?
DPP-4 inhibitors
Sodium-glucose linked transporter (SGLT): effect
proximal tubule of the kidney
Dapagliflozin
o Canagliflozin
o Empagliflozin
what are these
Sodium glucose linked transporter, add on has 2nd of 3rd therapy with metformin